PIK3CA mutation status, progression, and survival in metastatic HR+/HER2- breast cancer: meta-analysis

Approximately 40% of HR-positive/HER2-negative metastatic breast cancer patients harbor PIK3CA mutations. A meta-analysis of 11 trials (33 study arms, 3,219 patients among whom 1,386 PIK3CA mutated and 1,833 PIK3CA wild type) found that PIK3CA mutation was associated with shorter PFS and OS among patients with HR+/HER2- MBC. The authors conclude that PIK3CA mutations have a negative prognostic value in patients with HR+/HER2- MBC.